Connection

W. Garvey to Diabetes Mellitus, Type 2

Back to Details
This is a "connection" page, showing publications W. Garvey has written about Diabetes Mellitus, Type 2.
W. Garvey
Connection Strength
10.878
Diabetes Mellitus, Type 2
  1. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022 10; 28(10):2083-2091.
    View in: PubMed
    Score: 0.440
  2. Examining the evidence for weight management in individuals with type 2 diabetes. Diabetes Obes Metab. 2022 08; 24(8):1411-1422.
    View in: PubMed
    Score: 0.429
  3. New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications. J Clin Endocrinol Metab. 2022 03 24; 107(4):e1339-e1347.
    View in: PubMed
    Score: 0.423
  4. Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: A nationwide cohort and modeling study. PLoS Med. 2020 08; 17(8):e1003232.
    View in: PubMed
    Score: 0.378
  5. Covid-19 & Obesity: Beyond Bmi. Endocr Pract. 2020 Aug; 26(8):923-925.
    View in: PubMed
    Score: 0.378
  6. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020 05; 43(5):1085-1093.
    View in: PubMed
    Score: 0.367
  7. Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study. Diabetes Care. 2019 06; 42(6):1104-1111.
    View in: PubMed
    Score: 0.343
  8. DYSGLYCEMIA-BASED CHRONIC DISEASE: AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS POSITION STATEMENT. Endocr Pract. 2018 Nov; 24(11):995-1011.
    View in: PubMed
    Score: 0.335
  9. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018 08; 85:32-37.
    View in: PubMed
    Score: 0.319
  10. Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release. Diabetes Care. 2017 07; 40(7):856-862.
    View in: PubMed
    Score: 0.301
  11. Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2016;39:1186-1201. Diabetes Care. 2017 02; 40(2):e21-e22.
    View in: PubMed
    Score: 0.297
  12. Ablation of the Duodenal Mucosa as a Strategy for Glycemic Control in Type 2 Diabetes: Role of Nutrient Signaling or Simple Weight Loss. Diabetes Care. 2016 12; 39(12):2108-2110.
    View in: PubMed
    Score: 0.293
  13. Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders. Postgrad Med. 2016 Aug; 128(6):591-7.
    View in: PubMed
    Score: 0.286
  14. Development of a Weighted Cardiometabolic Disease Staging (CMDS) System for the Prediction of Future Diabetes. J Clin Endocrinol Metab. 2015 Oct; 100(10):3871-7.
    View in: PubMed
    Score: 0.267
  15. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action. Curr Obes Rep. 2015 Jun; 4(2):287-302.
    View in: PubMed
    Score: 0.264
  16. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014 Dec; 37(12):3309-16.
    View in: PubMed
    Score: 0.252
  17. BMI, RQ, diabetes, and sex affect the relationships between amino acids and clamp measures of insulin action in humans. Diabetes. 2014 Feb; 63(2):791-800.
    View in: PubMed
    Score: 0.236
  18. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014 Apr; 37(4):912-21.
    View in: PubMed
    Score: 0.236
  19. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity (Silver Spring). 2014 Jan; 22(1):110-8.
    View in: PubMed
    Score: 0.234
  20. New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). J Diabetes Complications. 2013 Sep-Oct; 27(5):508-18.
    View in: PubMed
    Score: 0.230
  21. Type 2 diabetes with partial lipodystrophy of the limbs: a new lipodystrophy phenotype. Diabetes Care. 2013 Aug; 36(8):2247-53.
    View in: PubMed
    Score: 0.226
  22. Mammalian Tribbles homolog 3 impairs insulin action in skeletal muscle: role in glucose-induced insulin resistance. Am J Physiol Endocrinol Metab. 2010 Mar; 298(3):E565-76.
    View in: PubMed
    Score: 0.181
  23. The genetic architecture of lipoprotein subclasses in Gullah-speaking African American families enriched for type 2 diabetes: the Sea Islands Genetic African American Registry (Project SuGAR). J Lipid Res. 2010 Mar; 51(3):586-97.
    View in: PubMed
    Score: 0.178
  24. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr. 2009 Jun; 139(6):1073-81.
    View in: PubMed
    Score: 0.173
  25. Genome-wide linkage scan in Gullah-speaking African American families with type 2 diabetes: the Sea Islands Genetic African American Registry (Project SuGAR). Diabetes. 2009 Jan; 58(1):260-7.
    View in: PubMed
    Score: 0.166
  26. Effects of short-term very low-calorie diet on intramyocellular lipid and insulin sensitivity in nondiabetic and type 2 diabetic subjects. Metabolism. 2008 Jan; 57(1):1-8.
    View in: PubMed
    Score: 0.158
  27. Estimation of resting energy expenditure considering effects of race and diabetes status. Diabetes Care. 2004 Jun; 27(6):1405-11.
    View in: PubMed
    Score: 0.123
  28. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003 Feb; 52(2):453-62.
    View in: PubMed
    Score: 0.112
  29. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes. Diabetes Res Clin Pract. 2002 Nov; 58(2):87-96.
    View in: PubMed
    Score: 0.110
  30. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023 02; 25(2):468-478.
    View in: PubMed
    Score: 0.110
  31. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022 Oct; 28(10):923-1049.
    View in: PubMed
    Score: 0.109
  32. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022 May; 28(5):528-562.
    View in: PubMed
    Score: 0.107
  33. Adipocytes exhibit abnormal subcellular distribution and translocation of vesicles containing glucose transporter 4 and insulin-regulated aminopeptidase in type 2 diabetes mellitus: implications regarding defects in vesicle trafficking. J Clin Endocrinol Metab. 2001 Nov; 86(11):5450-6.
    View in: PubMed
    Score: 0.103
  34. Case presentation and panel discussion: Cardiometabolic risk mitigation. JPEN J Parenter Enteral Nutr. 2021 11; 45(S2):93-99.
    View in: PubMed
    Score: 0.103
  35. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring). 2020 06; 28(6):1050-1061.
    View in: PubMed
    Score: 0.093
  36. Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes. Int J Obes (Lond). 2020 05; 44(5):990-998.
    View in: PubMed
    Score: 0.091
  37. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY. Endocr Pract. 2020 01; 26(1):107-139.
    View in: PubMed
    Score: 0.091
  38. CLINICAL PRACTICE GUIDELINES FOR THE PERIOPERATIVE NUTRITION, METABOLIC, AND NONSURGICAL SUPPORT OF PATIENTS UNDERGOING BARIATRIC PROCEDURES - 2019 UPDATE: COSPONSORED BY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY, THE OBESITY SOCIETY, AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY, OBESITY MEDICINE ASSOCIATION, AND AMERICAN SOCIETY OF ANESTHESIOLOGISTS - EXECUTIVE SUMMARY. Endocr Pract. 2019 Dec; 25(12):1346-1359.
    View in: PubMed
    Score: 0.090
  39. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. Endocr Pract. 2019 01; 25(1):69-100.
    View in: PubMed
    Score: 0.085
  40. Effects of mutations in the human uncoupling protein 3 gene on the respiratory quotient and fat oxidation in severe obesity and type 2 diabetes. J Clin Invest. 1998 Oct 01; 102(7):1345-51.
    View in: PubMed
    Score: 0.083
  41. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. Endocr Pract. 2018 01; 24(1):91-120.
    View in: PubMed
    Score: 0.079
  42. APPLICATION OF THE AACE/ACE ADVANCED FRAMEWORK FOR THE DIAGNOSIS OF OBESITY AND CARDIOMETABOLIC DISEASE STAGING IN A GENERAL POPULATION FROM 3 REGIONS OF VENEZUELA: THE VEMSOLS STUDY RESULTS. Endocr Pract. 2018 Jan; 24(1):6-13.
    View in: PubMed
    Score: 0.078
  43. Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. PLoS Med. 2017 Sep; 14(9):e1002383.
    View in: PubMed
    Score: 0.077
  44. Muscle Rad expression and human metabolism: potential role of the novel Ras-related GTPase in energy expenditure and body composition. Diabetes. 1997 Mar; 46(3):444-50.
    View in: PubMed
    Score: 0.075
  45. Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial. J Diabetes Complications. 2017 May; 31(5):891-897.
    View in: PubMed
    Score: 0.074
  46. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. Endocr Pract. 2017 02; 23(2):207-238.
    View in: PubMed
    Score: 0.074
  47. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. Endocr Pract. 2016 Jan; 22(1):84-113.
    View in: PubMed
    Score: 0.069
  48. Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: Stability of metabolic health status in adults. Obesity (Silver Spring). 2016 Feb; 24(2):516-25.
    View in: PubMed
    Score: 0.069
  49. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. Endocr Pract. 2015 Dec; 21(12):1403-14.
    View in: PubMed
    Score: 0.068
  50. Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care. 2015 Aug; 38(8):1567-82.
    View in: PubMed
    Score: 0.067
  51. Cardiovascular risk in Gullah African Americans with high familial risk of type 2 diabetes mellitus: project SuGAR. South Med J. 2014 Oct; 107(10):607-14.
    View in: PubMed
    Score: 0.063
  52. Glucose transporter proteins and insulin sensitivity in humans. Braz J Med Biol Res. 1994 Apr; 27(4):933-9.
    View in: PubMed
    Score: 0.061
  53. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr; 19(2):327-36.
    View in: PubMed
    Score: 0.056
  54. Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids. PLoS One. 2012; 7(11):e48852.
    View in: PubMed
    Score: 0.055
  55. Skeletal muscle lipid peroxidation and insulin resistance in humans. J Clin Endocrinol Metab. 2012 Jul; 97(7):E1182-6.
    View in: PubMed
    Score: 0.053
  56. Gene expression of GLUT4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. Diabetes. 1992 Apr; 41(4):465-75.
    View in: PubMed
    Score: 0.053
  57. Glucose transport and NIDDM. Diabetes Care. 1992 Mar; 15(3):396-417.
    View in: PubMed
    Score: 0.053
  58. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012 Jan; 14(1):40-6.
    View in: PubMed
    Score: 0.052
  59. Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. J Clin Invest. 1991 Mar; 87(3):1072-81.
    View in: PubMed
    Score: 0.049
  60. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS One. 2010 Dec 10; 5(12):e15234.
    View in: PubMed
    Score: 0.048
  61. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010 Jul-Aug; 16(4):629-40.
    View in: PubMed
    Score: 0.047
  62. A diabetes-specific enteral formula improves glycemic variability in patients with type 2 diabetes. Diabetes Technol Ther. 2010 Jun; 12(6):419-25.
    View in: PubMed
    Score: 0.047
  63. Insulin resistance and noninsulin-dependent diabetes mellitus: which horse is pulling the cart? Diabetes Metab Rev. 1989 Dec; 5(8):727-42.
    View in: PubMed
    Score: 0.045
  64. Intracellular lipid accumulation in liver and muscle and the insulin resistance syndrome. Endocrinol Metab Clin North Am. 2008 Dec; 37(4):841-56.
    View in: PubMed
    Score: 0.042
  65. Correlation of in vivo and in vitro actions of insulin in obesity and noninsulin-dependent diabetes mellitus: role of the glucose transport system. Diabetes Metab Rev. 1988 Sep; 4(6):543-69.
    View in: PubMed
    Score: 0.041
  66. Effect of two carbohydrate-modified tube-feeding formulas on metabolic responses in patients with type 2 diabetes. Nutrition. 2008 Oct; 24(10):990-7.
    View in: PubMed
    Score: 0.041
  67. Day-long integrated serum insulin and C-peptide profiles in patients with NIDDM. Correlation with urinary C-peptide excretion. Diabetes. 1988 May; 37(5):590-9.
    View in: PubMed
    Score: 0.040
  68. Role of glucose transporters in the cellular insulin resistance of type II non-insulin-dependent diabetes mellitus. J Clin Invest. 1988 May; 81(5):1528-36.
    View in: PubMed
    Score: 0.040
  69. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 2007 Jun; 18(3):263-70.
    View in: PubMed
    Score: 0.038
  70. Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women. Diabetes. 2006 Dec; 55(12):3630-4.
    View in: PubMed
    Score: 0.037
  71. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes. 2006 Jan; 55(1):249-59.
    View in: PubMed
    Score: 0.034
  72. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985 Mar; 34(3):222-34.
    View in: PubMed
    Score: 0.032
  73. Modulation of insulin secretion by insulin and glucose in type II diabetes mellitus. J Clin Endocrinol Metab. 1985 Mar; 60(3):559-68.
    View in: PubMed
    Score: 0.032
  74. A role for the Agouti-Related Protein promoter in obesity and type 2 diabetes. Biochem Biophys Res Commun. 2001 Sep 21; 287(2):568-73.
    View in: PubMed
    Score: 0.026
  75. Expression of mRNAs encoding uncoupling proteins in human skeletal muscle: effects of obesity and diabetes. Diabetes. 1998 Dec; 47(12):1935-40.
    View in: PubMed
    Score: 0.021
  76. Cloning of Rab GTPases expressed in human skeletal muscle: studies in insulin-resistant subjects. Horm Metab Res. 1998 Nov; 30(11):656-62.
    View in: PubMed
    Score: 0.021
  77. An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. Am J Hum Genet. 1998 Oct; 63(4):1130-8.
    View in: PubMed
    Score: 0.021
  78. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Am J Med. 1998 Oct; 105(4):331-45.
    View in: PubMed
    Score: 0.021
  79. An autosomal genomic scan for loci linked to prediabetic phenotypes in Pima Indians. J Clin Invest. 1998 Apr 15; 101(8):1757-64.
    View in: PubMed
    Score: 0.020
  80. Structure and organization of the human uncoupling protein 2 gene and identification of a common biallelic variant in Caucasian and African-American subjects. Diabetes. 1998 Apr; 47(4):685-7.
    View in: PubMed
    Score: 0.020
  81. Identification of Rad's effector-binding domain, intracellular localization, and analysis of expression in Pima Indians. J Cell Biochem. 1997 Jun 15; 65(4):527-41.
    View in: PubMed
    Score: 0.019
  82. The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab. 1997 Apr; 82(4):1293-300.
    View in: PubMed
    Score: 0.019
  83. Acylcarnitines as markers of exercise-associated fuel partitioning, xenometabolism, and potential signals to muscle afferent neurons. Exp Physiol. 2017 01 01; 102(1):48-69.
    View in: PubMed
    Score: 0.018
  84. TRANSCULTURALIZATION RECOMMENDATIONS FOR DEVELOPING LATIN AMERICAN CLINICAL PRACTICE ALGORITHMS IN ENDOCRINOLOGY--PROCEEDINGS OF THE 2015 PAN-AMERICAN WORKSHOP BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY. Endocr Pract. 2016 Apr; 22(4):476-501.
    View in: PubMed
    Score: 0.017
  85. Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. Metab Syndr Relat Disord. 2014 Oct; 12(8):422-9.
    View in: PubMed
    Score: 0.015
  86. Cellular insulin action and insulin resistance. Baillieres Clin Endocrinol Metab. 1993 Oct; 7(4):785-873.
    View in: PubMed
    Score: 0.015
  87. Muscle group-specific regulation of GLUT 4 glucose transporters in control, diabetic, and insulin-treated diabetic rats. Metabolism. 1993 Oct; 42(10):1310-5.
    View in: PubMed
    Score: 0.015
  88. Cellular mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes. Am J Med. 1988 Nov 28; 85(5A):86-105.
    View in: PubMed
    Score: 0.011
  89. Insulin resistance in non-insulin dependent (type II) and insulin dependent (type I) diabetes mellitus. Adv Exp Med Biol. 1985; 189:176-205.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.